Welcome to our dedicated page for Aclarion SEC filings (Ticker: ACON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Aclarion, Inc. (NASDAQ: ACON), a healthcare technology company that uses Magnetic Resonance Spectroscopy (MRS), proprietary signal processing, biomarkers, and augmented intelligence algorithms to support the diagnosis of chronic low back pain. Investors and analysts can review Aclarion’s official regulatory disclosures, including current reports, registration statements, and other filings submitted through the EDGAR system.
For ACON, SEC filings are a primary source of information on financing activities, capital structure, and strategic priorities. For example, a Form 8-K dated October 13, 2025 describes a Securities Purchase Agreement for a registered direct offering of common stock and pre-funded warrants, including expected gross proceeds, pricing terms, and intended use of proceeds. The filing also outlines the role of the placement agent and references the effective Form S-3 registration statement used for the offering.
Through this filings page, users can locate Aclarion’s periodic and transactional filings that detail how the company funds market development, clinical evidence generation, the CLARITY trial, product development and quality, and general corporate purposes. These documents help explain how Aclarion supports commercialization of its Nociscan SaaS platform and its broader strategy in the chronic low back pain market.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, financial implications, and risk factors in plain language. Real-time updates from EDGAR ensure that new 8-Ks, registration statements, and related documents appear promptly. Users can also review filings that relate to equity offerings and other capital markets activities, gaining a clearer view of Aclarion’s liquidity, financing approach, and commitments. This combination of raw filings and AI explanations allows readers to understand complex legal and financial disclosures without parsing every technical detail themselves.
Aclarion, Inc. has authorized a stock repurchase program of up to $2.5 million of its outstanding common shares. The company expects to carry out repurchases over the next 12 months, using methods such as open market purchases, block trades, privately negotiated deals, and 10b5-1 plans.
Aclarion plans to fund the program with existing cash and cash equivalents. As of March 31, 2026, it held approximately $19.0 million in cash and cash equivalents, which management believes is sufficient to support operations through key milestones, including the initial milestone of the CLARITY randomized trial.
Management describes the buyback as part of disciplined capital allocation and states they believe the current share price does not fully reflect the company’s Nociscan platform and long-term growth opportunity. The program is flexible and may be suspended, modified, or discontinued at any time.
Aclarion, Inc. is soliciting proxies for its 2026 Annual Meeting to be held June 4, 2026. Shareholders of record as of April 10, 2026 may vote on: (1) election of seven directors, (2) ratification of Haynie & Company as auditor, and (3) an amendment to the 2022 Equity Incentive Plan to increase the share reserve to 500,000 and raise per-participant annual limits.
The board recommends a vote FOR all proposals. Proxy materials and the 2025 Annual Report are available at the link provided in the notice. Attendance is in person only at the company’s Broomfield, Colorado offices.
SEG Opportunity Fund, LLC reports beneficial ownership of 244,043 shares of Aclarion, Inc. common stock, equal to 9.98% of the class. The filing states this position is based on 2,444,871 shares outstanding as of March 25, 2026. The statement lists shared voting and dispositive power over the 244,043 shares and is signed by Joseph Reda as Manager.
Aclarion, Inc. adopted a limited-duration stockholder rights plan that issues one right for each share of common stock and each Rights-Eligible Warrant outstanding as of March 30, 2026. Each right lets holders buy one one-thousandth of a share of Series D Junior Participating Preferred Stock at $14.00, subject to adjustment.
The plan is triggered if a person or group acquires 10% or more of common stock without board approval, with existing holders at or above that level grandfathered so long as they do not increase ownership. If triggered, other holders can buy securities at a 2x value multiple, diluting the acquirer.
The plan expires on March 18, 2027 unless earlier redeemed for $0.001 per right, exchanged into common or preferred shares, or terminated in connection with a board-approved merger. Aclarion also designated 10,000 shares of Series D Junior Participating Preferred Stock to support the plan.
Aclarion, Inc. is a healthcare technology company focused on improving diagnosis and treatment planning for chronic low back and neck pain using Magnetic Resonance Spectroscopy (MRS), proprietary biomarkers and cloud software. Its main product, NOCISCAN, analyzes disc chemistry to help clinicians identify which spinal discs are likely pain generators.
The company targets the U.S. low back and neck pain market, cited at $134.5 billion annually, initially focusing on surgical decision support for discogenic low back pain and then expanding to conservative and regenerative therapies. Aclarion is building clinical evidence, including studies published in the European Spine Journal, and holds an intellectual property portfolio of 28 U.S. patents, 24 foreign patents and multiple pending applications, many licensed exclusively from the Regents of the University of California. It is also pursuing reimbursement through Category III CPT codes and growing commercial adoption in the U.S. and U.K.
Aclarion, Inc. reported that it has closed a previously disclosed registered direct offering of its common stock and pre-funded warrants. Under a Securities Purchase Agreement dated January 8, 2026, the company agreed to sell 200,000 shares of common stock at a price of $5.18 per share, or pre-funded warrants in lieu of shares, and pre-funded warrants to purchase up to 1,800,000 additional shares of common stock. The company stated in a January 13, 2026 press release that this offering closed on January 9, 2026.
Aclarion, Inc. entered into a Securities Purchase Agreement for a registered direct offering of 200,000 shares of common stock at $5.18 per share and pre-funded warrants to purchase up to 1,800,000 additional shares. The pre-funded warrants are immediately exercisable at an exercise price of $0.00001 per share and remain exercisable until fully exercised, subject to beneficial ownership caps of 4.99% or 9.99% unless adjusted with 61 days’ notice.
The company expects gross proceeds of about $10.36 million before fees and expenses and may receive nominal additional proceeds from any cash exercises of the pre-funded warrants. Aclarion plans to use net proceeds to fund market development and clinical evidence, The Clarity Trial, product development and quality, and general and administrative support and other general corporate purposes.
Aclarion, Inc. is conducting a primary offering of 200,000 shares of common stock and pre-funded warrants to purchase 1,800,000 shares, together with 1,800,000 shares issuable upon exercise of those pre-funded warrants. The securities are priced at $5.18 per share and $5.17999 per pre-funded warrant, for a total offering price of $10,359,982 and placement agent fees of $621,600, resulting in $9,738,382 in proceeds before expenses and estimated net proceeds of about $9.6 million.
The company plans to use the cash to fund market development and clinical evidence work, The Clarity Trial, product development and quality, and general and administrative support. Pre-funded warrants have a $0.00001 exercise price, do not expire, are subject to 4.99% (or, at the purchaser’s election, 9.99%) beneficial ownership limits, and will not be listed for trading. Common shares outstanding were 854,371 as of January 8, 2026 and are expected to be 2,854,371 assuming full cash exercise of the pre-funded warrants.
Aclarion, Inc. (ACON) reported Q3 2025 results. Revenue was $18,942, up modestly from $14,407 a year ago, with gross profit of $4,386 after a loss in the prior year period. Operating expenses rose to $1.84 million, leading to a net loss of $1.71 million versus $1.37 million a year earlier. For the first nine months, revenue reached $57,251 and net loss was $5.34 million.
The balance sheet strengthened following capital raises: cash and cash equivalents were $11.34 million versus $0.45 million at year‑end 2024, total assets were $13.20 million, liabilities were $0.70 million, and stockholders’ equity improved to $12.50 million. The company disclosed it raised an additional $2.5 million in October 2025 and believes its cash will fund operations through the first quarter of 2027. During 2025, Aclarion effected 1:335 and 1:27 reverse stock splits. Shares outstanding were 582,371 as of September 30, 2025; as context, 671,371 shares were outstanding as of November 10, 2025.
Aclarion, Inc. entered into a Securities Purchase Agreement for a registered direct offering, selling 64,000 shares of common stock at $8.36 per share and issuing pre-funded warrants to purchase up to 236,000 shares. The company expects approximately $2.5 million in gross proceeds, with closing anticipated on or about October 14, 2025, subject to customary conditions.
The pre-funded warrants are immediately exercisable at an exercise price of $0.00001 and include a beneficial ownership cap of 4.99% or 9.99%, adjustable with 61 days’ prior notice. Dawson James Securities is the exclusive placement agent and will receive a 7.0% cash fee on gross proceeds plus expense reimbursement. Aclarion plans to use net proceeds to fund market development and clinical evidence, The Clarity Trial, product development and quality, and general and administrative support, and other general corporate purposes.